OpiCalc Logo

OpiCalc

989 Clinical Tools

Logo
OpiCalc
ACE-III (Cognitive Examination)AIMS (Tardive Dyskinesia)ASRM (Altman Mania Scale)ASRS-v1.1 (Adult ADHD Screen)ASSIST (WHO Substance Screen)AUDIT (Alcohol Use Disorders)AUDIT-C (Alcohol Screen)BARS (Akathisia)BDI-II (Beck Depression)BPRS (Brief Psychiatric Rating)BSDS (Bipolar Spectrum Screen)C-SSRS (Suicide Severity)CAGE QuestionnaireCAPS-5 (PTSD Clinical Interview)CDR (Dementia Staging)CDSS (Schizophrenia Depression)CIWA-Ar (Alcohol Withdrawal)COWS (Opioid Withdrawal)Clozapine Safety (REMS)DAST-10 (Drug Abuse Screen)DES-II (Dissociation Scale)EDE-Q (Eating Disorder Severity)EPDS (Postnatal Depression)Epworth Sleepiness ScaleFAST (Alzheimer's Staging)Fagerstrom (Nicotine Dependence)GAD-2 (Anxiety Screen)GAD-7 (Anxiety Severity)GAF (Global Functioning)HAM-D 17 (Hamilton Depression)HCL-32 (Hypomania Checklist)IES-R (Trauma Impact)ISI (Insomnia Severity)LSAS (Social Anxiety)MADRS (Depression Rating)MARSIPAN (Medical Risk in AN)MDQ (Bipolar Screen)MSI-BPD (Borderline PD Screen)Manchester Self-Harm RuleMetabolic Syndrome (Psych)MoCA (Cognitive Assessment)OCI-R (OCD Screen)PANSS (Schizophrenia Severity)PCL-5 (PTSD Checklist DSM-5)PHQ Panic ModulePHQ-2 (Depression Screen)PHQ-9 (Depression Severity)PSP (Personal/Social Performance)PSQI (Pittsburgh Sleep Quality)QTc Prolongation (Psychiatry)SAD PERSONS ScaleSAFE-T ProtocolSBQ-R (Suicidal Behaviors)SCOFF (Eating Disorder Screen)SPIN (Social Phobia)Simpson-Angus Scale (EPS)Y-BOCS (OCD Severity)YMRS (Mania Severity)
OpiCalc Logo

OpiCalc

Open-access clinical infrastructure. Built to the standard every clinician deserves — fast, private, and free.

Zero data stored
Always free
Our mission & transparency

Get in Touch

Tool request, clinical feedback, or partnership inquiry — we read everything.

WhatsApp feedback
Email us
Partnership inquiry

© 2026 OpiCalc • Calculated Care

ProtocolsAboutPrivacyTerms

Y-BOCS (OCD Severity)

Yale-Brown Obsessive Compulsive Scale (Y-BOCS)

Evaluate the severity of Obsessions and Compulsions. Scoring is based on clinical interviews regarding the past week.

I. Obsessions

Q1. Time spent on obsessions

Q2. Interference from obsessions

Q3. Distress from obsessions

Q4. Resistance against obsessions

Q5. Control over obsessions

II. Compulsions

Q6. Time spent on compulsions

Q7. Interference from compulsions

Q8. Distress from compulsions

Q9. Resistance against compulsions

Q10. Control over compulsions

© OpiCalc Psychiatry

Goodman WK. (1989)

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Clinical Utility

The "gold standard" for measuring the severity and type of symptoms in patients with Obsessive-Compulsive Disorder (OCD).
Monitoring response to treatment (Pharmacotherapy or Exposure and Response Prevention - ERP).
Determining the degree of functional impairment related to obsessions and compulsions.
Differentiating between clinical OCD and subclinical intrusive thoughts.
Section 2

Formula & Logic

Scoring Structure

The scale assesses 10 items: 5 for Obsessions (Time, Interference, Distress, Resistance, Control) and 5 matching items for Compulsions. Each is rated 0-4.

Severity Cutoffs

Score 0–7Subclinical
Score 8–15Mild
Score 16–23Moderate
Score 24–31Severe
Score 32–40Extreme
Section 3

Pearls/Pitfalls

Resistance vs. Control

Resistance (how hard the patient tries to stop) is often distinct from Control (how successful they are). In late-stage or severe OCD, "Resistance" may drop as the patient becomes exhausted or hopeless, even while "Control" is 0.

Clinical Pearls

A 25% to 35% reduction in Y-BOCS score is generally considered a "clinically significant response" in treatment trials.
Always perform a symptom checklist before the 10-item core assessment to identify the target obsessions/compulsions.
Distinguish between genuine obsessions and "depressive ruminations" or "delusions" which require different therapeutic approaches.
Section 4

Next Steps

Therapeutic Targets

01
Mild (8–15): Consider specialized CBT (specifically ERP) as first-line. SSRI therapy can be adjunctive.
02
Moderate (16–23): Combined ERP and high-dose SSRI (e.g., Fluoxetine 40-80mg, Sertraline 200mg+) is often necessary.
03
Severe (> 24): High risk of profound functional disability. Consider Clomipramine or SSRI augmentation with atypical antipsychotics.
04
Treatment Refractory: If multiple trials fail, evaluate for intensive outpatient or residential OCD programs.
Section 5

Evidence Appraisal

Primary Reference

The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability

Goodman WK et al. • Archives of General Psychiatry. 1989;Vol 46, Issue 11. pp. 1006-1011. The seminal study introducing the Y-BOCS.

Section 6

Literature

Wayne Goodman

Developed by Wayne Goodman and colleagues at Yale University. It transitioned OCD assessment from qualitative "yes/no" checklists to a quantitative measure of symptom burden.

Last Comprehensive Review: 2026

Related Psychiatry Tools

Inventory of Depressive Symptomatology
Patient Health Questionnaire for Adolescents
Alzheimer's Disease Assessment Scale — Cognitive
Eating Attitudes Test
Binge Eating Scale
Clinical Impairment Assessment
HAM-D 17
BDI-II
GAD-7
GAD-2
Have feedback about this calculator?Let us know.